Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
ADC Therapeutics SA Market Cap
Based on ratings from 7 stock analysts, the ADC Therapeutics SA stock price is expected to increase by 161.68% in 12 months. This is calculated by using the average 12-month stock price forecast for ADC Therapeutics SA. The lowest target is $6 and the highest is $10. Please note analyst price targets are not guaranteed and could be missed completely.
About 7 Wall Street analysts have assignedADCT 6 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect ADC Therapeutics SA to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ADCT. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ADCT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Sudan Loganathan Stephens & Co. | Overweight | $6 | Initiates | Nov 8, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $8 | Reiterates | Aug 8, 2024 |
| Gregory Renza RBC Capital | Outperform | $8 | Reiterates | Aug 7, 2024 |
| Eric Schmidt Cantor Fitzgerald | Overweight | Initiates | May 30, 2024 | |
| Robert Burns HC Wainwright & Co. | Buy | $8 | Maintains | May 7, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $9 | Reiterates | Apr 15, 2024 |
| Michael Schmidt Guggenheim | Buy | Reiterates | Apr 5, 2024 | |
| Michael Schmidt Guggenheim | Buy | $11 | Initiates | Mar 28, 2024 |
| Gregory Renza RBC Capital | Outperform | $8 | Reiterates | Mar 14, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $9 | Reiterates | Mar 6, 2024 |
| Gregory Renza RBC Capital | Outperform | $8 | Maintains | Feb 26, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $9 | Maintains | Feb 20, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $3 | Maintains | Nov 20, 2023 |
| Boris Peaker TD Cowen | Market Perform | Downgrade | Nov 9, 2023 | |
| Gregory Renza RBC Capital | Outperform | $6 | Maintains | Nov 8, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $12 | Reiterates | Sep 19, 2023 |
| Gregory Renza RBC Capital | Outperform | $8 | Maintains | Sep 12, 2023 |
| Brian Cheng JP Morgan | Neutral | Upgrade | Aug 10, 2023 | |
| Gregory Renza RBC Capital | Outperform | $9 | Maintains | Aug 9, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $12 | Reiterates | Jul 25, 2023 |
When did it IPO
2020
Staff Count
273
Country
Switzerland
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Ameet Mallik M.B.A., M.S.
Market Cap
$234.0M
In 2023, ADCT generated $69.6M in revenue, which was a decrease of -66.86% from the previous year. This can be seen as a signal that ADCT's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - ADC Therapeutics reported ZYNLONTA's Phase 2 trial results for r/r follicular lymphoma, showing a 97% overall response rate and a 77% complete response rate. Data published in The Lancet Haematology.
Why It Matters - Strong clinical results for ZYNLONTA in treating relapsed follicular lymphoma may boost ADC Therapeutics' market position and attract investor interest, indicating potential revenue growth.
Fri, 06 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - ADC Therapeutics SA will host a corporate update webcast on December 11, 2024, at 8:30 a.m. EST to discuss preliminary data from the LOTIS-7 trial regarding ZYNLONTA® and COLUMVI™.
Why It Matters - The webcast will reveal preliminary data on a key clinical trial, impacting ADC Therapeutics' stock performance and future growth prospects in cancer treatment.
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - ADC Therapeutics SA granted options to purchase 34,900 common shares to three new employees on December 2, 2024, as an inducement for their employment.
Why It Matters - The granting of stock options to new employees can signal confidence in future growth, potentially affecting stock value and investor sentiment regarding ADC Therapeutics' performance.
Sat, 09 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - ADC Therapeutics SA will hold its Q3 2024 earnings conference call on November 7, 2024, at 8:30 AM ET, featuring key executives and analysts from various firms.
Why It Matters - The upcoming Q3 2024 earnings call for ADC Therapeutics will provide insights into financial performance and strategic direction, influencing investor sentiment and stock performance.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - ADC Therapeutics (ADCT) will report LOTIS-5 enrollment and LOTIS-7 efficacy updates by late 2024. The company is discontinuing the ADCT-601 program, focusing on exatecan for solid tumors.
Why It Matters - The updates on LOTIS trials and the shift to prioritize exatecan-based treatments signal strategic focus and potential growth, impacting ADC Therapeutics' market positioning and investor confidence.
Fri, 08 Nov 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - ADC Therapeutics is navigating a competitive oncology market, but an analyst projects a potential 100% price upside for the company's stock.
Why It Matters - ADC Therapeutics' potential 100% upside signals strong growth prospects, despite market competition, indicating a lucrative investment opportunity in the oncology sector.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
